This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Researchers and company from Luxembourg awarded a grant from Michael J. Fox Foundation

December 14th, 2012

The Michael J. Fox Foundation grant will be used to study the "Modulation of the CD40/CD40-Ligand neuroinflammatory pathway in Parkinson's preclinical models."

This project could open a new avenue for therapeutic interventions in Parkinson's disease, where current approaches are limited mainly to dopaminergic replacement therapies. Dr. Djalil Coowar, AxoGlia's CSO and Principal Investigator, and his colleague at LSCB, Dr. Manuel Buttini, expect that by blocking neuroinflammation through the disruption of the CD40-CD40L pathway, a neuroprotective, disease-modifying effect will be achieved.

"Modulating neuroinflammation in Parkinson's disease could prove to be of therapeutic benefit and we are grateful to The Michael J. Fox Foundation for their support to our innovative strategies that identify neurorestorative and neuroprotective drug candidates," said AxoGlia's CEO Jean-Paul Scheuren.

Provided by University of Luxembourg

Citation: Researchers and company from Luxembourg awarded a grant from Michael J. Fox Foundation (2012, December 14) retrieved 3 August 2026 from https://sciencex.com/wire-news/116939202/researchers-and-company-from-luxembourg-awarded-a-grant-from-mic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.